FDA Permits Marketing of Clinical Decision Support Software for Alerting Providers of a Potential Stroke in Patients

FDAToday, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.

A stroke is a serious medical condition that requires emergency care and can cause lasting brain damage, long-term disability or even death. A stroke occurs if the flow of oxygen-rich blood to a portion of the brain is blocked, also known as an occlusion. According to the Centers for Disease Control and Prevention, stroke is the fifth leading cause of death in the U.S. and is a major cause of serious disability for adults. About 795,000 people in the U.S. have a stroke each year.

"Strokes can cause serious and irreversible damage to patients. The software device could benefit patients by notifying a specialist earlier thereby decreasing the time to treatment. Faster treatment may lessen the extent or progression of a stroke," said Robert Ochs, Ph.D., acting deputy director for radiological health, Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

The Viz.AI Contact application is a computer-aided triage software that uses an artificial intelligence algorithm to analyze images for indicators associated with a stroke. Artificial intelligence algorithms are a type of clinical decision support software that can assist providers in identifying the most appropriate treatment plan for a patient’s disease or condition. The FDA is currently creating a regulatory framework for these products that encourages developers to create, adapt and expand the functionalities of their software to aid providers in diagnosing and treating diseases and conditions.

The Viz.AI Contact application is designed to analyze CT images of the brain and send a text notification to a neurovascular specialist if a suspected large vessel blockage has been identified. The algorithm will automatically notify the specialist during the same time the first-line provider is conducting a standard review of the images, potentially involving the specialist sooner than the usual standard of care in which patients wait for a radiologist to review CT images and notify a neurovascular specialist. The notification can be sent to a mobile device, such as a smart phone or tablet, but the specialist still needs to review the images on a clinical workstation.

The Viz.AI Contact application is intended to be used by neurovascular specialists, such as vascular neurologists, neuro-interventional specialists or other professionals with similar training. The application is limited to analysis of imaging data and should not be used as a replacement of a full patient evaluation or solely relied upon to make or confirm a diagnosis.

The company submitted a retrospective study of 300 CT images that assessed the independent performance of the image analysis algorithm and notification functionality of the Viz.AI Contact application against the performance of two trained neuro-radiologists for the detection of large vessel blockages in the brain. Real-world evidence was used with a clinical study to demonstrate that the application could notify a neurovascular specialist sooner in cases where a blockage was suspected.

The Viz.AI Contact application was reviewed through the De Novo premarket review pathway, a regulatory pathway for some new types of medical devices that are low to moderate risk and have no legally marketed predicate device to base a determination of substantial equivalence. This action also creates a new regulatory classification, which means that subsequent computer-aided triage software devices with the same medical imaging intended use may go through the FDA's premarket notification (510 (k)) process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The FDA permitted marketing of the Contact application to Viz.AI.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Most Popular Now

Digital Health Consultancy Expands to Su…

Digital health consultancy Populo Consulting has announced the appointment of a new managing director as part of an ambitious growth strategy. The expansion will enable it to support more NHS...

Alcon to Develop SMART Suite Digital Hea…

Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to...

Stanford, Apple Describe Heart Study wit…

A clinical trial to determine whether a smartwatch app that analyzes pulse-rate data can screen for a heart-rhythm disorder has enrolled more than 400,000 participants. Researchers at Stanford Medicine, in...

The Partnership for Digital Healthis Com…

15 - 16 November 2018, Berlin, Germany. The initiative co-founded by Egon Zehnder and including partners Sanofi, SAP and Qiagen, is one of the most forward-thinking partnerships for promoting innovation in...

With Mobilett Elara Max, Siemens Healthi…

With the presentation of Mobilett Elara Max, Siemens Healthineers is setting new standards in mobile X-ray imaging. The easy-to-clean system surfaces with an antimicrobial coating reduce the risk of hospital...

Augmented Reality may Assist Cardiologis…

Augmented reality (AR), a technology that superimposes computer-generated information on a user's view of the real world, offers a new platform to help physicians better visualize complex medical data, particularly...

Health Tech Communications Agency Takes …

Highland Marketing, a full service marketing communications agency for the health tech and wider public sector markets, has appointed Michelle Cheng as marketing executive to support the business' rapid growth.

IBM to Acquire Red Hat, Completely Chang…

IBM (NYSE:IBM) and Red Hat (NYSE:RHT), the world's leading provider of open source cloud software, announced that the companies have reached a definitive agreement under which IBM will acquire all...

Open Call SC1-DTH-05-2019: Large Scale I…

An ageing population is increasing demand-side pressures on public health and social care providers across Europe. These pressures undermine the long-term sustainability of existing models for delivering care services to...

Robotic Arm may Help to Rehabilitate Chr…

New research published in Frontiers in Neurology finds that robotic arm rehabilitation in chronic stroke patients with aphasia, the loss of ability to understand or express speech, may promote speech...

Breakthrough Neurotechnology for Treatin…

Three paraplegics who sustained cervical spinal cord injuries many years ago are now able to walk with the aid of crutches or a walker thanks to new rehabilitation protocols that...